Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
about
The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trialExendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob miceLong-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamusCardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsDevelopment of minimally invasive techniques for management of medically-complicated obesityImpact of postprandial glycaemia on health and prevention of diseaseGLP-1-based strategies: a physiological analysis of differential mode of actionOmega-3 Fatty Acids and FFAR4GLP-1, the gut-brain, and brain-periphery axesReversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese miceCrystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 ReceptorGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesNutritional modulation of endogenous glucagon-like peptide-1 secretion: a reviewPeripheral signals mediate the beneficial effects of gastric surgery in obesityThe relationship between gut and adipose hormones, and reproductionLiraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic miceThe glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodentsCorrelative Confocal and 3D Electron Microscopy of a Specific Sensory CellAntiobesity pharmacotherapy: new drugs and emerging targetsCurrent trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.New advances in models and strategies for developing anti-obesity drugs.The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.Oral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion.Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsThe effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trialNeuroactive peptides as putative mediators of antiepileptic ketogenic diets.Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetesEfficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitusObesity treatment: novel peripheral targets.Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implicationsGLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsThe GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.Obesity pharmacotherapy: what is next?Antiobesity pharmacotherapy in the management of type 2 diabetes.Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).Counterregulation of insulin by leptin as key component of autonomic regulation of body weight.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
P2860
Q21245681-79D9ED50-3463-4508-870E-9943AFEF946AQ24629441-677CADB7-2C94-44BB-A8D7-A375D0D288EBQ26749191-E4074C97-0A08-4BC6-9AA1-E9C4CCA2A110Q26823085-0386EF44-A230-4D28-92ED-7A9F4560C3FBQ26851369-C73F57A5-5F9F-411C-BA4B-54846A199568Q26862823-05DACE40-DB88-435D-BFA4-69ACC1764284Q26997149-86A3626F-6A58-40F0-902B-848614789E86Q27000272-CDBF1461-279A-4326-8DDF-2CF227056142Q27000749-D7C8538D-7770-4A9C-B8B6-FAD2FEEC7E69Q27316004-F7F0F647-F1D0-40F7-936D-1C9158957A1CQ27657999-B5A3D677-87E8-410D-8FDD-5323AD9EA696Q28067465-DEF854B1-A141-4B97-A4E8-D38BC78DB704Q28070256-8CEC766C-6571-4C34-9D9E-B3C813332E5AQ28088425-7F4E94A1-88F5-460C-B4DB-C53B19935228Q28301116-9511A8E6-7E2B-446C-A0CD-5EFDD9168B9EQ28546996-A7BDD918-BBEF-42E1-A4DC-871BCBD49F62Q28598004-D8DAA1D7-C17C-4EAB-8D21-66DD6FDAE984Q28608626-688AA928-80E3-4B92-B93A-D112556B627AQ30354242-783E4403-0940-41EA-A4BB-C3533BFBDD60Q30399390-991C3FDA-4646-4CB4-A267-EB01E7084087Q30403705-9270AD6D-9522-4678-886C-F9E1490B2E68Q30429816-281E9B2C-CFAA-49E9-84D4-3E4118DB2D9CQ30596646-BBFEC504-3F35-4568-8277-3B70E3DE1FB1Q31115560-E64215F9-58FD-4895-9A99-A4DCD8371634Q33521451-60064BE2-5784-4F65-8F3F-0FD2C526B1B2Q33566838-2DF6BA26-CB7D-485D-8BF5-11AF38EDA087Q33569276-903A8301-BD28-41B4-A064-087D2951B76EQ33570118-DE490B3C-C088-403F-B9F1-74B1A410A2ADQ33585560-6647175B-0E66-46E7-85A1-85A260B0DEC5Q33607742-F1E4C458-424E-415A-A2AC-DBAE61CAF704Q33607971-2CDBCC62-77E3-4D9B-B4FD-9478DA6F73C6Q33717424-2D414EAD-CABB-41E7-9E52-4F66030184FEQ33734024-14DE3BF3-216F-4894-B13B-70D2E679B5F0Q33737073-34AC2518-8C09-40CE-A109-9B0303AF672CQ33787829-F8F073EB-BAAF-4933-A31F-B059377EE870Q33827988-85797542-D2FD-4F56-BE7B-D03696074425Q33883725-C46CD543-37A7-4BD0-BF85-F5CA83365872Q33960291-B88AAB28-21BA-42A7-81D3-0A5EC0471928Q34068418-8FCBC6B4-89EF-4AE5-841A-DC20ACF92EE1Q34068749-02FC4FCD-B0D1-4FA5-AB6D-A1BEA3A783F1
P2860
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@en
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@nl
type
label
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@en
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@nl
prefLabel
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@en
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@nl
P2860
P356
P1476
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
@en
P2860
P304
P356
10.1172/JCI990
P407
P577
1998-02-01T00:00:00Z